(Q43035175)

English

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial

scientific article published in October 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

H L Bonkovsky

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D Stefancyk

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

K McNeal

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

B F Banner

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Q Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

G M Zucker

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Israel

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Stagias

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Colker

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2051-2059

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

https://scigraph.springernature.com/pub.10.1023/a:1011919906194

0 references

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of hepatitis C: other options

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Iron and chronic viral hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes research in chronic viral hepatitis C: effects of interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/11680575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1011919906194

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43035175&oldid=1978266928"